Daniel Solvie
Overview
Explore the profile of Daniel Solvie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reissland M, Hartmann O, Tauch S, Bugter J, Prieto-Garcia C, Schulte C, et al.
Oncogene
. 2025 Jan;
44(5):336.
PMID: 39843564
No abstract available.
2.
Reissland M, Hartmann O, Tauch S, Bugter J, Prieto-Garcia C, Schulte C, et al.
Oncogene
. 2024 Oct;
43(50):3645-3659.
PMID: 39443725
The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that...
3.
Mamontova V, Trifault B, Gribling-Burrer A, Bohn P, Boten L, Preckwinkel P, et al.
Genes Dev
. 2024 Oct;
38(17-20):915-930.
PMID: 39362776
Long noncoding (lnc)RNAs emerge as regulators of genome stability. The nuclear-enriched abundant transcript 1 (NEAT1) is overexpressed in many tumors and is responsive to genotoxic stress. However, the mechanism that...
4.
Trifault B, Mamontova V, Cossa G, Ganskih S, Wei Y, Hofstetter J, et al.
Nucleic Acids Res
. 2024 Jan;
52(6):3050-3068.
PMID: 38224452
RNA-binding proteins emerge as effectors of the DNA damage response (DDR). The multifunctional non-POU domain-containing octamer-binding protein NONO/p54nrb marks nuclear paraspeckles in unperturbed cells, but also undergoes re-localization to the...
5.
Henriksson S, Calderon-Montano J, Solvie D, Berglund U, Helleday T
Biomolecules
. 2022 Dec;
12(12).
PMID: 36551206
Previously, we reported that MTH1 inhibitors TH588 and TH1579 selectively induce oxidative damage and kill Ras-expressing or -transforming cancer cells, as compared to non-transforming immortalized or primary cells. While this...
6.
Solvie D, Baluapuri A, Uhl L, Fleischhauer D, Endres T, Papadopoulos D, et al.
Nature
. 2022 Nov;
612(7938):148-155.
PMID: 36424410
Oncoproteins of the MYC family drive the development of numerous human tumours. In unperturbed cells, MYC proteins bind to nearly all active promoters and control transcription by RNA polymerase II....
7.
Papadopoulos D, Solvie D, Baluapuri A, Endres T, Ha S, Herold S, et al.
Mol Cell
. 2021 Nov;
82(1):159-176.e12.
PMID: 34847357
The MYCN oncoprotein drives the development of numerous neuroendocrine and pediatric tumors. Here we show that MYCN interacts with the nuclear RNA exosome, a 3'-5' exoribonuclease complex, and recruits the...
8.
Endres T, Solvie D, Heidelberger J, Andrioletti V, Baluapuri A, Ade C, et al.
Mol Cell
. 2021 Jan;
81(4):830-844.e13.
PMID: 33453168
The MYC oncoprotein globally affects the function of RNA polymerase II (RNAPII). The ability of MYC to promote transcription elongation depends on its ubiquitylation. Here, we show that MYC and...
9.
Herold S, Kalb J, Buchel G, Ade C, Baluapuri A, Xu J, et al.
Nature
. 2019 Mar;
567(7749):545-549.
PMID: 30894746
MYC is an oncogenic transcription factor that binds globally to active promoters and promotes transcriptional elongation by RNA polymerase II (RNAPII). Deregulated expression of the paralogous protein MYCN drives the...